Business Context and Reporting Period
Company: MEDICINOVA INC
Filing Type: Form 8-K (Regulation FD Disclosure)
Date: February 26, 2016
Context: The Company filed a Japanese report ("Kessan Tanshin") with the Tokyo Stock Exchange containing financial results for the year ended December 31, 2015, and providing a financial forecast for 2016. The 2015 results are substantially the same as the Company's Form 10-K.
Key Financial Metrics and Guidance
The filing does not provide historical revenue, profit, or cash flow figures for the year ended December 31, 2015, referring instead to the Form 10-K. However, it provides the following forward-looking financial estimates for 2016:
| Period | Revenues | Operating Loss | Net Loss | Loss Per Share (Basic/Diluted) |
|---|---|---|---|---|
| Interim (6 months ended June 30, 2016) | $0 | $5,229,000 | $5,229,000 | $0.16 |
| Full Year (ended Dec 31, 2016) | $0 | $10,254,000 | $10,254,000 | $0.31 |
Note: Loss per share calculations assume a weighted average of 32,300,000 shares.
Material Changes and Supplementary Information
- Currency Translation: Supplementary financial statements denominated in Japanese yen were translated at a rate of 120.87 JPY per USD (Telegraphic Transfer Middle Rate as of January 29, 2016).
- Revenue Outlook: The forecast indicates zero expected revenue for both the interim and full-year periods in 2016.
Risks, Contingencies, and Management Commentary
Management emphasizes that the forecast is based on assumptions regarding current conditions and trends, which are subject to significant risks and uncertainties beyond the Company's control. Key risks include:
- Regulatory and Clinical Risks: Potential delays or failures in clinical trials, regulatory approvals, or unexpected adverse side effects of product candidates.
- Capital Resources: Uncertainty in credit and capital markets affecting the ability to raise sufficient capital or debt financing.
- Commercialization: Intense competition and market potential uncertainties if products are commercialized.
- Auditor Disclaimer: The Company's independent auditors have not compiled or reviewed the forecasted results and assume no responsibility for their accuracy.
The filing includes standard forward-looking statement disclaimers under the Private Securities Litigation Reform Act of 1995.
Investor Verification Checklist
- Verify the historical financial results for the year ended December 31, 2015, in the Company's Form 10-K, as specific numbers are not included in this 8-K.
- Confirm the current weighted average number of shares outstanding, as the forecast relies on an assumed 32,300,000 shares.
- Review the "Risk Factors" section of the Form 10-K for detailed disclosures regarding clinical trial progress and capital needs.
- Monitor subsequent filings for updates on the Company's ability to raise capital given the projected net losses and zero revenue forecast.